

COMPANY PROFILE

At TransEnterix, Inc., we are digitizing the interface between the surgeon and the patient to improve minimally invasive surgery (MIS) through a new category of care we call Digital Laparoscopy. Digitizing the interface enables the use of advanced capabilities like augmented intelligence, connectivity and robotics in laparoscopy, and allows us to address the current clinical, cognitive and economic shortcomings in surgery.

COMPANY SNAPSHOT

Stock Symbol: TRXC

Stock Exchange: NYSE American

Headquarters: Research Triangle Park, NC

- Active sites in **15 countries across the US, EU, and Asia**
- **FDA, CE Mark, and PMDA approved**
- **>3,700 surgeries performed** to date
- **140** global employees
- **>100** surgeon users

DIGITIZING MINIMALLY INVASIVE SURGERY (LAPAROSCOPY)

SENHANCE® SURGICAL SYSTEM

First and only Digital Laparoscopy surgical robotic platform globally.



AUGMENTED INTELLIGENCE

First surgical robotic system with Augmented Intelligence capabilities.



SURGEON BENEFIT

- Enhanced control during surgery with surgeon eye-tracking camera control & 3DHD vision
- Enhanced precision through tremor filtrations and robotic stabilization
- Enhanced focus during surgery through optimized ergonomics and the sense of touch (haptics) for the first time in robotic surgery

HOSPITAL BENEFIT

- Per-procedure cost similar to traditional laparoscopy
- Highly configurable, allowing hospitals to use existing operating room infrastructure

PATIENT BENEFIT

- Smallest instruments offered in robotics leading to >50% smaller incisions vs traditional robotic surgery

2020 STRATEGIC PRIORITIES

MARKET DEVELOPMENT

Building awareness & demonstrating clinical and economic value.

CLINICAL VALIDATION


Developing clinical evidence to support the value propositions of Senhance.

PORTFOLIO EXPANSION

Broadening the applicability of Senhance by adding new indications, features, and instruments.

MARKET OPPORTUNITY

The abdominal robotic surgery market currently has a very low penetration into the surgical market and is projected to grow at a **double digit CAGR over the foreseeable future.**¹



Senhance is well positioned for success in the unaddressed laparoscopic surgical market.

CLINICAL PERFORMANCE TRENDS

- Strong global active sites growth from 2018 to 2020
- 30 installations globally
- 192% increase in clinical case volume from 2018 to 2019
- Well balanced use across multiple surgical specialty areas (general, gynecology, urology, colorectal and bariatric)

UPCOMING CLINICAL MILESTONES

- Receive CE Mark for Intelligent Surgical Unit™ (ISU™) in Europe, Q4 2020
- Receive FDA 510(k) for General Surgery indication expansion, Q1 2021
- File FDA 510(k) for next generation ISU, Q1 2021
- File FDA 510(k) for articulating instruments, Q1 2021

MANAGEMENT TEAM



ANTHONY FERNANDO
President & CEO



WESLEY LONG
VP of Customer Excellence



CAMERON PEDERSEN, PH.D.
VP of Global Research & Development



SHAMEZE RAMPERTAB
Executive VP & CFO

FORWARD-LOOKING STATEMENT

The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for certain forward-looking statements. The forward-looking statements contained in this document are subject to certain risks and uncertainties. Actual results could differ materially from current expectations. The information contained herein is not a prospectus and does not constitute an offer to sell nor a solicitation of an offer to buy any security.

Learn more at [TransEnterix.com](https://www.transenterix.com)